High Dose Trastuzumab + Pertuzumab for HER2+ Brain Mets

“In the phase II PATRICIA trial reported in the Journal of Clinical Oncology, Nancy U. Lin, MD, and colleagues found that pertuzumab plus high-dose trastuzumab produced central nervous system (CNS) objective responses and clinical benefit in 68% of patients with HER2-positive metastatic breast cancer with progressive brain metastases.“

Full article -

https://ascopost.com/news/may-2021/pertuzumabhigh-dose-trastuzumab-in-patients-with-her2-positive-metastatic-breast-cancer-and-progressive-brain-metastases/

Report of study results (pdf file)

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.02822